Evidence map›Paper›PMID 8102388›Full record

ArticleThe Journal of experimental medicine1993

Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.

A D'Andrea, M Aste-Amezaga, N M Valiante, X Ma, M Kubin, G Trinchieri

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 413 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
413citing papers in PubMed, 2 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

413 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,396 citations in OpenAlex.

  1. Interleukin-10-1082A/G polymorphism and diabetic nephropathy: a meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Protective Effects of RecombinantAnimals : an open access journal from MDPI · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

353 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A D'AndreaThe Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.
M Aste-Amezaga
N M Valiante
X Ma
M Kubin
G Trinchieri
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 1985 to 2026
$75.9M
CELL-MEDIATED CYTOTOXICITY IN HUMANSR01CA020833 · NCI · WISTAR INSTITUTE · PI KAUFMAN, RUSSEL E. · 1985 to 2003
$1.9M
DIFFERENTIATION AND FUNCTION OF MONOCYTESR01CA032898 · NCI · WISTAR INSTITUTE · PI SANTOLI, DANIELA · 1985 to 1994
–
CELL-MEDIATED CYTOTOXICITY IN HUMANSR37CA020833 · NCI · WISTAR INSTITUTE · PI TRINCHIERI, GIORGIO · 1990 to 1998
–
NCI NIH HHS CA-10815NCI NIH HHS CA-20833NCI NIH HHS CA-32898
6 · The paper itself

Abstract

Natural killer cell stimulatory factor or interleukin 12 (NKSF/IL-12) is a heterodimeric cytokine produced by monocytes/macrophages, B cells, and possibly other accessory cell types primarily in response to bacteria or bacterial products. NKSF/IL-12 mediates pleiomorphic biological activity on T and NK cells and, alone or in synergy with other inducers, is a powerful stimulator of interferon gamma (IFN-gamma) production. IL-10 is a potent inhibitor of monocyte-macrophage activation, that inhibits production of tumor necrosis factor alpha (TNF-alpha), IL-1 and also IFN-gamma from lymphocytes acting at the level of accessory cells. Because TNF-alpha and IL-1 are not efficient inducers of IFN-gamma, the mechanism by which IL-10 inhibits IFN-gamma production is not clear. In this paper, we show that IL-10 is a potent inhibitor of NKSF/IL-12 production from human peripheral blood mononuclear cells activated with Staphylococcus aureus or lipopolysaccharide (LPS). Both the production of the free NKSF/IL-12 p40 chain and the biologically active p70 heterodimer are blocked by IL-10. NKSF/IL-12 p40 chain mRNA accumulation is strongly induced by S. aureus or LPS and downregulated by IL-10, whereas the p35 mRNA is constitutively expressed and only minimally regulated by S. aureus, LPS, or IL-10. Although IL-10 is able to block the production of NKSF/IL-12, a powerful inducer of IFN-gamma both in vitro and in vivo, the mechanism of inhibition of IFN-gamma by IL-10 cannot be explained only on the basis of inhibition of NKSF/IL-12 because IL-10 can partially inhibit IFN-gamma production induced by NKSF/IL-12, and also, the IFN-gamma production in response to various stimuli in the presence of neutralizing antibodies to NKSF/IL-12. Our findings that antibodies against NKSF/IL-12, TNF-alpha, or IL-1 beta can significantly inhibit IFN-gamma production in response to various stimuli and that NKSF/IL-12 and IL-1 beta can overcome the IL-10-mediated inhibition of IFN-gamma, suggest that IL-10 inhibition of IFN-gamma production is primarily due to its blocking production from accessory cells of the IFN-gamma-inducer NKSF/IL-12, as well as the costimulating molecule IL-1 beta.

Indexed as

Antigen-Presenting CellsGene ExpressionHumansInterferon-gammaInterleukin-1Interleukin-10Interleukin-12InterleukinsIn Vitro TechniquesLeukocytes, MononuclearRecombinant ProteinsRNA, MessengerTumor Necrosis Factor-alphaInterferon-gammaInterleukin-1Interleukin-10Interleukin-12InterleukinsRecombinant ProteinsRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID8102388
PMCPMC2191152
OpenAlexW2115954882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.